GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eris Lifesciences Ltd (NSE:ERIS) » Definitions » Cyclically Adjusted PS Ratio

Eris Lifesciences (NSE:ERIS) Cyclically Adjusted PS Ratio : 13.07 (As of Jun. 03, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Eris Lifesciences Cyclically Adjusted PS Ratio?

As of today (2025-06-03), Eris Lifesciences's current share price is ₹1566.10. Eris Lifesciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₹119.86. Eris Lifesciences's Cyclically Adjusted PS Ratio for today is 13.07.

The historical rank and industry rank for Eris Lifesciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

NSE:ERIS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 11.02   Med: 12.18   Max: 13.21
Current: 13.21

During the past years, Eris Lifesciences's highest Cyclically Adjusted PS Ratio was 13.21. The lowest was 11.02. And the median was 12.18.

NSE:ERIS's Cyclically Adjusted PS Ratio is ranked worse than
95.26% of 738 companies
in the Drug Manufacturers industry
Industry Median: 2.13 vs NSE:ERIS: 13.21

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Eris Lifesciences's adjusted revenue per share data for the three months ended in Mar. 2025 was ₹51.498. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹119.86 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eris Lifesciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Eris Lifesciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eris Lifesciences Cyclically Adjusted PS Ratio Chart

Eris Lifesciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 11.82

Eris Lifesciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 11.82

Competitive Comparison of Eris Lifesciences's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eris Lifesciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eris Lifesciences's Cyclically Adjusted PS Ratio falls into.


;
;

Eris Lifesciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Eris Lifesciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1566.10/119.86
=13.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eris Lifesciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Eris Lifesciences's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=51.498/157.5517*157.5517
=51.498

Current CPI (Mar. 2025) = 157.5517.

Eris Lifesciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201303 0.000 85.687 0.000
201403 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201606 13.323 105.961 19.810
201609 14.467 105.961 21.511
201612 13.408 105.196 20.081
201703 13.370 105.196 20.024
201706 13.465 107.109 19.806
201709 16.666 109.021 24.085
201712 15.103 109.404 21.750
201803 15.135 109.786 21.720
201806 17.928 111.317 25.374
201809 18.934 115.142 25.908
201812 18.077 115.142 24.735
201903 15.328 118.202 20.431
201906 19.766 120.880 25.763
201909 20.359 123.175 26.041
201912 19.012 126.235 23.728
202003 17.918 124.705 22.637
202006 21.197 127.000 26.296
202009 23.945 130.118 28.994
202012 22.434 130.889 27.004
202103 20.191 131.771 24.141
202106 25.293 134.084 29.720
202109 25.994 135.847 30.147
202112 24.126 138.161 27.512
202203 22.159 138.822 25.149
202206 28.810 142.347 31.887
202209 33.458 144.661 36.439
202212 30.725 145.763 33.210
202303 29.054 146.865 31.168
202306 33.801 150.280 35.437
202309 36.739 151.492 38.209
202312 35.482 152.924 36.556
202403 40.209 153.035 41.396
202406 52.478 155.789 53.072
202409 54.217 157.882 54.104
202412 53.017 158.323 52.759
202503 51.498 157.552 51.498

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eris Lifesciences  (NSE:ERIS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Eris Lifesciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Eris Lifesciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eris Lifesciences Business Description

Traded in Other Exchanges
Address
Ramdas Road, Plot No. 142/2, Shivarth Ambit, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, GJ, IND, 380054
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast.

Eris Lifesciences Headlines

No Headlines